These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 16247065

  • 1. An open study of botulinum-A toxin treatment of trigeminal neuralgia.
    Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD.
    Neurology; 2005 Oct 25; 65(8):1306-8. PubMed ID: 16247065
    [Abstract] [Full Text] [Related]

  • 2. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial.
    Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ.
    Neurology; 2009 Apr 28; 72(17):1473-8. PubMed ID: 19246421
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin.
    Schulte-Mattler WJ, Opatz O, Blersch W, May A, Bigalke H, Wohlfahrt K.
    J Neurol Sci; 2007 Sep 15; 260(1-2):38-42. PubMed ID: 17481662
    [Abstract] [Full Text] [Related]

  • 4. An open study of botulinum-A toxin treatment of trigeminal neuralgia.
    Zakrzewska JM, Cohen J, Brown J, Alksne J, Gemillion H, Linskey M, Sirois D, Pollock B.
    Neurology; 2006 May 09; 66(9):1458-9; author reply 1458-9. PubMed ID: 16685762
    [No Abstract] [Full Text] [Related]

  • 5. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.
    Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L.
    Pain; 2009 Jan 09; 141(1-2):60-9. PubMed ID: 19004549
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.
    Ranoux D, Attal N, Morain F, Bouhassira D.
    Ann Neurol; 2008 Sep 09; 64(3):274-83. PubMed ID: 18546285
    [Abstract] [Full Text] [Related]

  • 7. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study.
    Taylor M, Silva S, Cottrell C.
    Headache; 2008 Sep 09; 48(10):1476-81. PubMed ID: 19076646
    [Abstract] [Full Text] [Related]

  • 8. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study.
    Dykstra DD, Presthus J.
    J Reprod Med; 2006 Jun 09; 51(6):467-70. PubMed ID: 16846084
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxins for analgesia.
    Smith HS.
    Pain Physician; 2009 Jun 09; 12(3):479-81. PubMed ID: 19461815
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study.
    Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M.
    Pain Med; 2006 Jun 09; 7(3):260-4. PubMed ID: 16712627
    [Abstract] [Full Text] [Related]

  • 11. Comparison of pulsed radiofrequency with conventional radiofrequency in the treatment of idiopathic trigeminal neuralgia.
    Erdine S, Ozyalcin NS, Cimen A, Celik M, Talu GK, Disci R.
    Eur J Pain; 2007 Apr 09; 11(3):309-13. PubMed ID: 16762570
    [Abstract] [Full Text] [Related]

  • 12. Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases.
    Shimohata K, Shimohata T, Motegi R, Miyashita K.
    Headache; 2009 May 09; 49(5):768-70. PubMed ID: 19456884
    [Abstract] [Full Text] [Related]

  • 13. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction.
    Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, Kamioka H, Yamashiro T, Kuboki T, Oguma K.
    Neuroscience; 2009 Apr 10; 159(4):1422-9. PubMed ID: 19409226
    [Abstract] [Full Text] [Related]

  • 14. Sumatriptan alleviates pain in patients with trigeminal neuralgia.
    Kanai A, Suzuki A, Osawa S, Hoka S.
    Clin J Pain; 2006 Oct 10; 22(8):677-80. PubMed ID: 16988562
    [Abstract] [Full Text] [Related]

  • 15. An open study of botulinum-A toxin treatment of trigeminal neuralgia.
    Brenner SR.
    Neurology; 2006 May 09; 66(9):1458-9; author reply 1458-9. PubMed ID: 16682696
    [No Abstract] [Full Text] [Related]

  • 16. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin.
    Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P.
    Pain; 2007 Jul 09; 130(1-2):76-83. PubMed ID: 17194546
    [Abstract] [Full Text] [Related]

  • 17. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia.
    Obermann M, Yoon MS, Ese D, Maschke M, Kaube H, Diener HC, Katsarava Z.
    Neurology; 2007 Aug 28; 69(9):835-41. PubMed ID: 17724285
    [Abstract] [Full Text] [Related]

  • 18. OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data.
    Kowacs PA, Utiumi MA, Nascimento FA, Piovesan EJ, Teive HA.
    Arq Neuropsiquiatr; 2015 Oct 28; 73(10):877-84. PubMed ID: 26291995
    [Abstract] [Full Text] [Related]

  • 19. An open study of botulinum-A toxin treatment of trigeminal neuralgia.
    Voller B, Sycha T, Gustorff B, Kranz G, Auff E.
    Neurology; 2006 May 09; 66(9):1458-9; author reply 1458-9. PubMed ID: 16685761
    [No Abstract] [Full Text] [Related]

  • 20. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
    Monheit GD, Cohen JL, Reloxin Investigational Group.
    J Am Acad Dermatol; 2009 Sep 09; 61(3):421-5. PubMed ID: 19577326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.